3 Strengths – 45 mg/4,5 ml; 50 mg/5 ml; 60 mg/6 ml


Cabazitaxel is a third-generation antineoplastic taxane and was the first therapy to show a survival benefit for the treatment of patients with docetaxel-refractory mCRPC.

Cabazitaxel EVER Pharma is provided as a single vial, ready to dilute formulation and is available in vial sizes covering the common range of patient specific doses for economy and convenience.

Learn more: www.evervalinject.com

Dosage forms.